COMMUNIQUÉS West-GlobeNewswire

Callio Therapeutics Appoints Chris Hassig, PhD, as Chief Scientific Officer
28/09/2026
Industry veteran brings more than two decades of oncology drug discovery leadership to advance Callio's dual-payload ADC pipeline SAN DIEGO and SEATTLE and SINGAPORE, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Callio [...]
ORYZON Receives European Medicines Agency Approval to Initiate the HOPE-2 Phase II Study of Vafidemstat for the Treatment of Phelan-McDermid Syndrome (PMS)
28/09/2026
PMS is a severely disabling genetic disorder related to autism U.S. prevalence is estimated at approximately 1 in 7,300 people HOPE-2 is partially funded through Oryzon’s VANDAM project under Med4Cure, an Important [...]
BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team
28/09/2026
New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray Brands ELLON, Scotland and LONDON, Sept. 28, 2026 (GLOBE NEWSWIRE [...]
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
28/09/2026
Preclinical data demonstrate prolonged KRAS target engagement and potent antitumor activity across multiple KRAS-mutant cancer models, supporting the continued advancement of BH-501284 toward an IND submission in Q1 [...]
Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation
28/09/2026
Binding term sheet with PsyLabs provides Psyence BioMed’s Texas subsidiary with exclusive U.S. development, supply and distribution rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to a definitive agreement NEW [...]
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
28/09/2026
FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic [...]
Tiziana Life Sciences Announces First Participants Dosed in ALS BANYAN Clinical Trial of Intranasal Foralumab
28/09/2026
BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development [...]
4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company’s Phase I Cell Therapy Program
28/09/2026
Collaboration extends existing relationship with the Tier 1 pharmaceutical customer into cell therapy programs End-to-end supply chain combines 4basebio's proprietary opDNA® enzymatic DNA starting material with TriLink' [...]
Eton Pharmaceuticals Announces U.S. Commercial Availability of IMPAVIDO® (miltefosine) Capsules
28/09/2026
Eton Pharmaceuticals now holds exclusive commercialization rights for IMPAVIDO in the United States Eton has integrated full Eton Cares ® patient support, including $0 co-pay for eligible commercially insured patients [...]
NOTICE TO DISREGARD -- Direct Meds
28/09/2026
New York City, NY, Sept. 28, 2026 (GLOBE NEWSWIRE) -- We are advised by Direct Meds that journalists and other readers should disregard the news release, "Direct Meds Updates DirectMax Clinical Review and Licensed- [...]
Flyte Named Official Air Travel Partner of the 34th Annual Hamptons International Film Festival
28/09/2026
Partnership Expands Flyte’s Growing Presence Across Entertainment, Fashion, Hospitality, Sports and Premium Destination Travel 2026 Flyte Breakthrough Awards will Honor Anthony Ippolito, Star of Amazon MGM Studios’ “I [...]
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
28/09/2026
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat LA JOLLA, Calif., Sept. 28, 2026 [...]
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
28/09/2026
Acquisition diversifies durable cash flows and advances Zymeworks’ strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI ® expected to contribute immediately [...]
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
28/09/2026
REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis , Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with [...]
Lift Therapeutics Appoints Eva Ehrnrooth as Executive Head of Clinical Development and Adds Chau Khuong to Board of Directors
28/09/2026
London, September 28, 2026 – Lift Therapeutics (‘Lift’ or ‘the Company’) today announced the appointment of Eva Ehrnrooth, MD, PhD, as Executive Head of Clinical Development and Chau Khuong to its Board of Directors. Dr [...]
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
28/09/2026
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug exposure limit provides greater dosing flexibility in future [...]
U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations
28/09/2026
NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN™ rapamycin has the potential to become the first FDA-approved therapy and [...]
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
28/09/2026
BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health need Non-dilutive funding for SCY- [...]
Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer
28/09/2026
Dr. Houvras brings over two decades of executive leadership across premier industry and academic research institutions in clinical development, translational medicine and immuno-oncology WALTHAM, Mass., Sept. 28, 2026 ( [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum